Literature DB >> 11259101

Inhibition of erythropoietin signalling destroys xenografts of ovarian and uterine cancers in nude mice.

Y Yasuda1, T Musha, H Tanaka, Y Fujita, H Fujita, H Utsumi, T Matsuo, S Masuda, M Nagao, R Sasaki, Y Nakamura.   

Abstract

We have recently shown that malignant tumours from the ovary and uterus expressed erythropoietin (Epo) and its receptor (EpoR), and that deprivation of Epo signal in tumour blocks induced death of malignant cells and capillary endothelial cells in vitro (Yasuda et al, submitted). These in vitro results prompted us to examine the effect of Epo-signal withdrawal on tumours in vivo. RT-PCR analysis demonstrated the expression of mRNAs for Epo and EpoR in the transplants of uterine and ovarian tumours in nude mice. Then we injected locally anti-Epo antibody or soluble form of EpoR into the transplants. At 12 h, 1, 7 or 14 days after the injection, all transplants were resected and examined macro- and microscopically. Tumour size was reduced in Epo signal-deprived transplants. Immunohistochemical examinations revealed destruction of Epo-responding malignant and capillary endothelial cells through apoptotic death. The degree of tumour regression correlated well with the dose and frequency of the injections. Control xenografts with saline injection or needle insertion showed well-developed tumour masses. This Epo response pathway will have profound implications for our understanding of the development and progression of malignant tumours and for the use of Epo-signal deprivation as an effective therapy. Copyright 2001 Cancer Research Campaign.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11259101      PMCID: PMC2363820          DOI: 10.1054/bjoc.2000.1666

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  29 in total

Review 1.  Erythropoietin: structure, control of production, and function.

Authors:  W Jelkmann
Journal:  Physiol Rev       Date:  1992-04       Impact factor: 37.312

Review 2.  Erythropoietin.

Authors:  S B Krantz
Journal:  Blood       Date:  1991-02-01       Impact factor: 22.113

Review 3.  Regulation of erythropoietin production.

Authors:  D L Porter; M A Goldberg
Journal:  Exp Hematol       Date:  1993-03       Impact factor: 3.084

4.  Inducible operation of the erythropoietin 3' enhancer in multiple cell lines: evidence for a widespread oxygen-sensing mechanism.

Authors:  P H Maxwell; C W Pugh; P J Ratcliffe
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-15       Impact factor: 11.205

Review 5.  Structure, function, and activation of the erythropoietin receptor.

Authors:  H Youssoufian; G Longmore; D Neumann; A Yoshimura; H F Lodish
Journal:  Blood       Date:  1993-05-01       Impact factor: 22.113

6.  Characterization and use of monoclonal antibodies directed against human erythropoietin that recognize different antigenic determinants.

Authors:  M Goto; A Murakami; K Akai; G Kawanishi; M Ueda; H Chiba; R Sasaki
Journal:  Blood       Date:  1989-09       Impact factor: 22.113

7.  Chemotherapy of human tumor xenografts in genetically athymic mice.

Authors:  A A Ovejera; D P Houchens; A D Barker
Journal:  Ann Clin Lab Sci       Date:  1978 Jan-Feb       Impact factor: 1.256

8.  Induced megakaryocytic maturation of the human leukemia cell line UT-7 results in down-modulation of erythropoietin receptor gene expression.

Authors:  N Komatsu; H Fujita
Journal:  Cancer Res       Date:  1993-03-01       Impact factor: 12.701

9.  Induction of avascular yolk sac due to reduction of basic fibroblast growth factor by retinoic acid in mice.

Authors:  Y Yasuda; N Nishi; J A Takahashi; H Konishi; I Ohara; H Fujita; M Ohta; N Itoh; M Hatanaka; T Tanimura
Journal:  Dev Biol       Date:  1992-04       Impact factor: 3.582

10.  Production and ligand-binding characteristics of the soluble form of murine erythropoietin receptor.

Authors:  M Nagao; S Masuda; S Abe; M Ueda; R Sasaki
Journal:  Biochem Biophys Res Commun       Date:  1992-10-30       Impact factor: 3.575

View more
  24 in total

1.  Anemia in cervical cancer patients: implications for iron supplementation therapy.

Authors:  Myrna Candelaria; Lucely Cetina; Alfonso Dueñas-González
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

Review 2.  Promises and pitfalls in erythopoietin-mediated tissue protection: are nonerythropoietic derivatives a way forward?

Authors:  Carla Cerami Hand; Michael Brines
Journal:  J Investig Med       Date:  2011-10       Impact factor: 2.895

3.  Epo is involved in angiogenesis in human glioma.

Authors:  Beatrice Nico; Tiziana Annese; Diego Guidolin; Nicoletta Finato; Enrico Crivellato; Domenico Ribatti
Journal:  J Neurooncol       Date:  2010-07-09       Impact factor: 4.130

4.  Limitations of a murine transgenic breast cancer model for studies of erythropoietin-induced tumor progression.

Authors:  Chris P Miller; Karine Valliant-Saunders; Carl Anthony Blau
Journal:  Transl Oncol       Date:  2010-06-01       Impact factor: 4.243

Review 5.  Association between pharmaceutical support and basic science research on erythropoiesis-stimulating agents.

Authors:  Charles L Bennett; Stephen Y Lai; Michael Henke; Sara E Barnato; James O Armitage; Oliver Sartor
Journal:  Arch Intern Med       Date:  2010-09-13

6.  Erythropoietin in thyroid cancer.

Authors:  C M Yates; A Patel; K Oakley; A Helms; R M Tuttle; G L Francis
Journal:  J Endocrinol Invest       Date:  2006-04       Impact factor: 4.256

7.  Functional erythropoietin autocrine loop in melanoma.

Authors:  Suresh M Kumar; Geza Acs; Dong Fang; Meenhard Herlyn; David E Elder; Xiaowei Xu
Journal:  Am J Pathol       Date:  2005-03       Impact factor: 4.307

8.  Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activities.

Authors:  Thomas R Coleman; Christof Westenfelder; Florian E Tögel; Ying Yang; Zhuma Hu; Leanne Swenson; Henri G D Leuvenink; Rutger J Ploeg; Livius V d'Uscio; Zvonimir S Katusic; Pietro Ghezzi; Adriana Zanetti; Kenneth Kaushansky; Norma E Fox; Anthony Cerami; Michael Brines
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-03       Impact factor: 11.205

9.  Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression.

Authors:  Geza Acs; Paul J Zhang; Cindy M McGrath; Peter Acs; John McBroom; Ahmed Mohyeldin; Suzhen Liu; Huasheng Lu; Ajay Verma
Journal:  Am J Pathol       Date:  2003-06       Impact factor: 4.307

10.  Erythropoietin promotes the growth of tumors lacking its receptor and decreases survival of tumor-bearing mice by enhancing angiogenesis.

Authors:  Tatsuma Okazaki; Satoru Ebihara; Masanori Asada; Shinsuke Yamanda; Kaijun Niu; Hiroyuki Arai
Journal:  Neoplasia       Date:  2008-09       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.